iShares Health Innovation Active ETF (ARCA: BMED)

Latest news for iShares Health Innovation Active ETF (ARCA:BMED)

Healthcare

Other

Basic Materials

Financial Services

To pursue its objective, the Fund will invest at least 80 percent of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. The Fund will consider a company to be principally engaged in the health sciences group of industries if it is classified in an industry within the health sciences group of industries by a third-party industry classification system or it is not classified in any industry by such third-party industry classification system and BFA determines that the company is principally engaged in the health sciences group of industries.

Blackrock Cash Funds: Treasury, Sl Agency Shares

Boston Scientific Corp.

Cencora Inc

Intuitive Surgical Inc.

Argenx Se

Alnylam Pharmaceuticals Inc Common Stock Usd 0.01

Mettler-Toledo International Inc.

West Pharmaceutical Services Inc

Amgen Inc 2.2 5/19

Danaher Corp.

BlackRock Future Health ETF

Trump Pulls US Out Of WHO On Day 1, Citing COVID-19 Mismanagement And Funding Disparities

Government

News

Regulations

Health Care

General

BMED

Harvard Apparatus Regenerative Technology

HART

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust S&P Global Healthcare Sector Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

PINK

Trump signs an order to withdraw the U.S. from WHO, citing pandemic mismanagement, political influence, and inequitable funding, reigniting a past debate.

World Health Organization Responds to Trump&#39;s Order, Reminds Decades of Successful Health Achievements

Biotech

ABBV

ALPMY

BIIB

CERE

FHLC

HTEC

IMGN

MDEV

MRTX

RETA

RYZB

SGEN

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. 

Upward Trajectory For Biotech/Pharma M&amp;A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

iShares Health Innovation Active ETF

<p>TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) has outperformed the market over the past 5 years by 1.92% on an annualized basis producing an average annual return of 15.08%. Currently, TD Synnex has a market capitalization of $11.92 billion. </p>
<p><strong>Buying $1000 In SNX:</strong> If an investor had bought $1000 of SNX stock 5 years ago, it would be worth <strong>$2,034.38</strong> today based on a price of $141.50 for SNX at the time of writing.</p>
<h3>TD Synnex's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737583212_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much You Would Have Made Owning TD Synnex Stock In The Last 5 Years

WIIM

Hexcel shares are trading lower after the company issued FY25 adjusted EPS guidance below estimates.

<p>Towne Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOWN#NASDAQ">TOWN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.48 by 14.58 percent. This is a 30.95 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $177.16 million which missed the analyst consensus estimate of $178.57 million by 0.79 percent. This is a 13.90 percent increase over sales of $155.55 million the same period last year.</p>


Earnings

TOWN

CORRECTION: Towne Bank Q4 Adj $0.55 Beats $0.48 Estimate, Sales $177.16M Miss $178.57M Estimate

<p>Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.91 by 14.29 percent.  The company reported quarterly sales of $58.289 million which beat the analyst consensus estimate of $55.960 million by 4.16 percent.</p>


Earnings Beats

EQBK

Equity Bancshares Q4 2024 GAAP EPS $1.04 Beats $0.91 Estimate, Sales $58.289M Beat $55.960M Estimate

NBBK

NB Bancorp Q4 2024 EPS $0.34 Beats $0.32 Estimate

<p><strong>QCR Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>QCR Hldgs beat estimated earnings by 10.0%, reporting an EPS of $1.93 versus an estimate of $1.76.</p>
<p>Revenue was up $5.47 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.26 which was followed by a 0.0% increase in the share price the next day.</p>
<p>Here's a look at QCR Hldgs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.52</td>
<td>1.40</td>
<td>1.30</td>
<td>1.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.78</td>
<td>1.73</td>
<td>1.59</td>
<td>1.97</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>61.47M</td>
<td>65.25M</td>
<td>63.77M</td>
<td>58.53M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>59.72M</td>
<td>56.16M</td>
<td>54.70M</td>
<td>55.74M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for QCR Hldgs <a href="https://www.benzinga.com/quote/QCRH/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QCRH

QCR Hldgs Earnings Analysis: Q4 Recap

<p><strong>Triumph Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:07 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Triumph Financial missed estimated earnings by -48.0%, reporting an EPS of $0.13 versus an estimate of $0.25.</p>
<p>Revenue was down $2.59 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.01 which was followed by a 5.0% increase in the share price the next day.</p>
<p>Here's a look at Triumph Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.18</td>
<td>0.22</td>
<td>0.34</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.19</td>
<td>0.08</td>
<td>0.14</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>107.30M</td>
<td>104.08M</td>
<td>106.01M</td>
<td>106.85M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>106.20M</td>
<td>105.08M</td>
<td>101.03M</td>
<td>106.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Triumph Financial <a href="https://www.benzinga.com/quote/TFIN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TFIN

Triumph Financial Earnings Analysis: Q4 Recap

<p>The earnings results for <strong>SL Green Realty</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) for Q4 were made public on Wednesday, January 22, 2025 at 04:10 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>SL Green Realty beat estimated earnings by 18.0%, reporting an EPS of $1.81 versus an estimate of $1.53.</p>
<p>Revenue was up $7.69 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company missed on EPS by $0.07, resulting in a 3.0% increase change in the share price the following day.</p>
<p>Here's a look at SL Green Realty's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.20</td>
<td>1.60</td>
<td>2.16</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.13</td>
<td>2.05</td>
<td>3.07</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>136.66M</td>
<td>149.28M</td>
<td>152.67M</td>
<td>161.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>139.62M</td>
<td>135.56M</td>
<td>128.20M</td>
<td>131.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SL Green Realty <a href="https://www.benzinga.com/quote/SLG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SL Green Realty Q4 Earnings Assessment

<p>The Q4 earnings report for <strong>Hexcel</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) was released on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hexcel missed estimated earnings by 0.0%, reporting an EPS of $0.52 versus an estimate of $0.52.</p>
<p>Revenue was up $16.30 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Hexcel's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.46</td>
<td>0.56</td>
<td>0.41</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.47</td>
<td>0.60</td>
<td>0.44</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>456.90M</td>
<td>483.36M</td>
<td>473.78M</td>
<td>471.69M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>456.50M</td>
<td>500.40M</td>
<td>472.30M</td>
<td>457.50M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hexcel <a href="https://www.benzinga.com/quote/HXL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Hexcel Q4 Earnings

<p>The earnings results for <strong>Plexus</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) for Q1 were made public on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Plexus beat estimated earnings by 9.0%, reporting an EPS of $1.73 versus an estimate of $1.59.</p>
<p>Revenue was down $6.88 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.3 in the last quarter, resulting in a 7.000000000000001% increase share price change the following day.</p>
<p>Here's a look at Plexus's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.55</td>
<td>1.30</td>
<td>0.87</td>
<td>1.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.85</td>
<td>1.45</td>
<td>0.94</td>
<td>1.04</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.01B</td>
<td>981.25M</td>
<td>950.83M</td>
<td>987.63M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.05B</td>
<td>961.00M</td>
<td>967.00M</td>
<td>983.00M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Plexus management provided guidance for Q2 2025, expecting earnings between $1.46 and $1.61 per share.</p>
<p>To track all earnings releases for Plexus <a href="https://www.benzinga.com/quote/PLXS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PLXS

Plexus: Q1 Earnings Insights

<p><strong>National Bank Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:10 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>National Bank Holdings beat estimated earnings by 12.0%, reporting an EPS of $0.86 versus an estimate of $0.77.</p>
<p>Revenue was up $600 thousand from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 8.0% increase share price change the next day.</p>
<p>Here's a look at National Bank Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.75</td>
<td>0.74</td>
<td>0.76</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.68</td>
<td>0.82</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>104.59M</td>
<td>102.96M</td>
<td>103.68M</td>
<td>103.96M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>106.04M</td>
<td>97.60M</td>
<td>101.72M</td>
<td>107.23M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for National Bank Holdings <a href="https://www.benzinga.com/quote/NBHC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NBHC

Earnings Breakdown: National Bank Holdings Q4

<p><strong>CACI International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) reported its Q2 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>CACI International beat estimated earnings by 13.0%, reporting an EPS of $5.95 versus an estimate of $5.25.</p>
<p>Revenue was up $266.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.86 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at CACI International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>5.07</td>
<td>5.93</td>
<td>5.63</td>
<td>4.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>5.93</td>
<td>6.61</td>
<td>5.74</td>
<td>4.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.92B</td>
<td>1.93B</td>
<td>1.86B</td>
<td>1.84B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.06B</td>
<td>2.04B</td>
<td>1.94B</td>
<td>1.83B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>CACI International management provided guidance for FY 2025, expecting earnings between $23.87 and $24.76 per share.</p>
<p>To track all earnings releases for CACI International <a href="https://www.benzinga.com/quote/CACI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CACI

CACI International Earnings Review: Q2 Summary

<p><strong>Third Coast Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Third Coast Bancshares beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.79 versus an estimate of $0.69.</p>
<p>Revenue was up $6.82 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat on EPS by $0.2 which was followed by a 6.0% increase in the share price the next day.</p>
<p>Here's a look at Third Coast Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.57</td>
<td>0.49</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.63</td>
<td>0.61</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>41.67M</td>
<td>41.13M</td>
<td>39.30M</td>
<td>38.13M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>42.90M</td>
<td>41.75M</td>
<td>40.42M</td>
<td>39.49M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Third Coast Bancshares <a href="https://www.benzinga.com/quote/TCBX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TCBX

Third Coast Bancshares Q4 Earnings Assessment

<p>The earnings results for <strong>Wesbanco</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) for Q4 were made public on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Wesbanco beat estimated earnings by 28.999999999999996%, reporting an EPS of $0.71 versus an estimate of $0.55.</p>
<p>Revenue was up $8.75 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.05, resulting in a 1.0% drop change in the share price the following day.</p>
<p>Here's a look at Wesbanco's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.53</td>
<td>0.55</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.56</td>
<td>0.49</td>
<td>0.56</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>120.74M</td>
<td>126.11M</td>
<td>116.83M</td>
<td>116.77M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>121.14M</td>
<td>116.59M</td>
<td>113.97M</td>
<td>117.76M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Wesbanco <a href="https://www.benzinga.com/quote/WSBC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WSBC

Wesbanco Earnings Analysis: Q4 Recap

<p><strong>Univest Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UVSP#NASDAQ">UVSP</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Univest Financial beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.65 versus an estimate of $0.57.</p>
<p>Revenue was up $5.42 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company beat on EPS by $0.09 which was followed by a 4.0% increase in the share price the next day.</p>
<p>Here's a look at Univest Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.51</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.63</td>
<td>0.61</td>
<td>0.60</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>73.20M</td>
<td>72.30M</td>
<td>72.20M</td>
<td>71.25M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>73.35M</td>
<td>72.01M</td>
<td>77.06M</td>
<td>71.38M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Univest Financial <a href="https://www.benzinga.com/quote/UVSP/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UVSP

Univest Financial Earnings Review: Q4 Summary

<p><strong>Equity Bancshares</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) just disclosed its Q4 earnings on Wednesday, January 22, 2025 at 04:45 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Equity Bancshares beat estimated earnings by 13.0%, reporting an EPS of $1.04 versus an estimate of $0.92.</p>
<p>Revenue was up $62.24 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.32, resulting in a 2.0% increase change in the share price the following day.</p>
<p>Here's a look at Equity Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.92</td>
<td>0.85</td>
<td>-1.88</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.31</td>
<td>0.99</td>
<td>0.90</td>
<td>-1.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>56.09M</td>
<td>55.15M</td>
<td>52.81M</td>
<td>29.49M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>55.35M</td>
<td>55.43M</td>
<td>55.91M</td>
<td>-3M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Equity Bancshares <a href="https://www.benzinga.com/quote/EQBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Equity Bancshares Q4

<p>Shares of solar stocks, including <strong>First Solar Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) and <strong>SolarEdge Technologies, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) were volatile Wednesday as investors reacted to President Donald Trump&#8217;s newly signed <a href="https://www.benzinga.com/25/01/43109461/gold-miners-defense-stocks-shine-while-solar-tanks-following-trumps-day-1-actions">executive orders promoting </a>fossil fuels and reversing climate-focused policies.</p>
<p><strong>What To Know: </strong> The sell-off followed Trump's inauguration and his immediate signature on executive orders prioritizing oil and gas development over renewable energy initiatives.</p>
<p>According to<a href="https://www.nytimes.com/2025/01/20/climate/trump-emergency-oil-gas.html"> the New York Times</a>, his administration announced plans to withdraw from the Paris Agreement, expand fossil fuel drilling on public lands and waters, and eliminate regulatory support for electric vehicles and renewable energy projects. Trump also declared a national energy emergency aimed at accelerating fossil fuel production, further unsettling renewable energy investors.</p>
<p>The market&#8217;s response may reflect concerns over the new administration's shift in energy policy, which contrasts sharply with the pro-renewable initiatives under the previous Biden administration. Analysts believe this pivot could slow the growth of the renewable energy sector and significantly impact solar companies, contributing to the downward pressure on their stock prices.</p>
<p><strong>Price Action: </strong>First Solar&#8217;s stock closed Wednesday at $171.90, down 6.33%, and SolarEdge Technologies closed at $13.05, down 4.74%, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43144023/riot-stock-poised-break-out-consolidation-cycle">Options Corner: Riot Platforms Could Be Itching To Charge Higher</a></strong></li>
</ul>
<p><em>Photo: solarseven on Shutterstock</em>.</p>


Movers

FSLR

SEDG

Solar Shares Are Volatile Today: What's Going On?

<p>CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.88 percent. This is a 7.69 percent decrease over earnings of $0.39 per share from the same period last year.</p>


CVBF

CVB Financial Q4 EPS $0.36 Beats $0.34 Estimate

BETR

Better Home & Finance shares are trading higher after the company announced a $25 million share repurchase program.

<p>Jean Madar, Chairman &amp; Chief Executive Officer of Interparfums, stated, "Our net sales in the final quarter of 2024 marked our best-ever fourth quarter performance, with quarterly sales growth of 10%, enabling us to achieve our 2024 sales goal of $1.45 billion."</p>
<p>Achieving the sales goal of $1.45 billion positions the Company to meet its full year 2024 earnings per diluted share target of $5.15, excluding a supplemental non-recurring, non-cash impairment charge of approximately $0.07 per diluted share, associated with trademarks.</p>


Guidance

IPAR

Interparfums Q4 Net Sales Up 10% To $362M, Est $361.807M

<p>President <strong>Donald Trump</strong> signed an executive order on January 20, 2025, initiating the United States&#8217; withdrawal from the World Health Organization (WHO).</p>



<p>The <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/01/withdrawing-the-united-states-from-the-worldhealth-organization/" rel="noreferrer noopener">move</a> marks a continuance of Trump&#8217;s first-term efforts to end WHO membership, citing concerns about the organization&#8217;s governance and financial practices. Former President Joe Biden reversed Trump&#8217;s initial withdrawal attempt upon taking office in 2021.</p>



<p>In his order, Trump pointed to the WHO&#8217;s handling of the COVID-19 pandemic, its alleged susceptibility to political influence, and a lack of meaningful reforms as primary reasons for the decision.</p>



<p>The U.S. has criticized the organization&#8217;s funding structure, emphasizing that American contributions far outweigh those of other nations. For example, China, with a population over three times that of the U.S., contributes approximately 90% less to the WHO&#8217;s budget, the executive order says.</p>



<p>The executive order formally <a target="_blank" href="https://www.nytimes.com/2025/01/20/us/politics/trump-world-health-organization.html" rel="noreferrer noopener">revokes</a> the 2021 Presidential Letter that retracted the U.S.&#8217;s initial notification to withdraw. Trump&#8217;s administration argued that WHO has failed to demonstrate independence from undue political influence and continues to impose unfair financial demands on the U.S.</p>



<p>The WHO said it <a target="_blank" href="https://www.who.int/news/item/21-01-2025-who-comments-on-united-states--announcement-of-intent-to-withdraw" rel="noreferrer noopener">regretted</a> the decision, emphasizing the historic partnership between the organization and the United States. As a founding member since 1948, the U.S. has played a significant role in shaping the WHO&#8217;s initiatives and policies.</p>



<p>The collaboration has led to major public health achievements, including the eradication of smallpox and the near-eradication of polio. WHO highlighted that American institutions have contributed to and benefited from the partnership over the past seven decades.</p>



<p>The U.S. decides to withdraw when global health challenges require coordinated efforts. While the WHO faces criticism, the organization argues that U.S. involvement has been critical to protecting Americans and addressing international health crises.</p>



<p><strong>Read Next:</strong></p>



<ul>
<li><strong><a href="https://www.benzinga.com/news/large-cap/25/01/43122667/oracle-unveils-ai-powered-sales-tools-to-boost-customer-engagements-details" target="_blank" rel="noreferrer noopener">Oracle Unveils AI-Powered Sales Tools To Boost Customer Engagements: Details</a></strong></li>
</ul>



<p><em>Image via Shutterstock</em></p>

World Health Organization Responds to Trump's Order, Reminds Decades of Successful Health Achievements

<p>According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.&nbsp;</p>

<p>Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&amp;A deals in&nbsp;<a class="editor-rtfLink" href="https://www.globaldata.com/store/report/healthcare-industry-m-and-a-deals-by-theme-quarterly-analysis/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Q3</a>&nbsp;2023.</p>

<p>PricewaterhouseCoopers&nbsp;<a class="editor-rtfLink" href="https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">wrote</a>&nbsp;in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. &quot;As regulators&#39; perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps.&quot;</p>

<p>&quot;Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty seems a given in 2024,&quot; PWC added in its report.</p>

<p>The pharmaceutical and life sciences sector experienced a notably robust year in 2023, nearing pre-pandemic levels in both M&amp;A deal value and volume, the PWC report added.&nbsp;</p>

<p>Anticipations for 2024 suggest continuing this trend, projecting comparable activity levels within the range of $225 billion to $275 billion across all subsectors.</p>

<p><strong>Notable Deals in 2023</strong></p>

<ul>
	<li><strong>Pfizer Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) acquired&nbsp;<strong>Seagen Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGEN#NASDAQ">SGEN</a>)<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">&nbsp;for $43 billion.</a></li>
	<li><strong>Bristol Myers Squibb &amp; Co</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bmy#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BMY</a>) agreed to acquire&nbsp;<strong>Karuna Therapeutics Inc</strong>&nbsp;KRTX for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/12/36360205/bristol-myers-squibb-scoops-up-schizophrenia-player-karuna-therapeutics-in-massive-14b-deal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">estimated cash acquired</a>.&nbsp;</li>
	<li><strong>Merck &amp; Co</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) acquired&nbsp;<strong>Prometheus Biosciences&nbsp;</strong>for $200.00 per share in cash for a total equity&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/08/33491400/merck-swings-into-q2-loss-on-prometheus-biosciences-acquisition-charge-but-raises-fy23-revenue-ou" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">value of ~$10.8 billion</a>.</li>
	<li><strong>AbbVie Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) to acquire&nbsp;<strong>ImmunoGen Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>) and its flagship cancer therapy Elahere, for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/11/36020779/immunogens-flagship-cancer-therapy-draws-abbvies-attention-with-10-1b-deal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $10.1 billion</a>.&nbsp;</li>
	<li><strong>AbbVie Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) will acquire psychiatric and neurological disorders player&nbsp;<strong>Cerevel Therapeutics Holdings, Inc&nbsp;</strong>(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/cere#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">CERE</a>) for $45 per share in cash with a total equity value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/12/36138161/why-cerevel-therapeutics-stock-is-higher" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $8.7 billion</a>.</li>
	<li><strong>Biogen Inc&nbsp;</strong>(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/biib#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BIIB</a>) agreed to acquire&nbsp;<strong>Reata Pharmaceuticals Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/reta#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">RETA</a>) for $172.50 per share in cash, reflecting an enterprise value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/07/33440534/biogen-bolsters-rare-disease-portfolio-agrees-to-buy-reata-pharmaceuticals-with-enterprise-value-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $7.3 billion</a>.</li>
	<li><strong>Bristol Myers Squibb &amp; Co</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bmy#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BMY</a>) agreed to purchase&nbsp;<strong>Mirati</strong>&nbsp;<strong>Therapeutics Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/mrtx#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">MRTX</a>) at $58.00 per share in cash, amounting to an overall equity valuation of $4.8 billion, with an additional Contingent Value Right at $12.00 per share in cash, offering an extra&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/10/35141493/bristol-myers-squibb-strengthens-oncology-portfolio-with-mirati-therapeutics-5b-deal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">$1.0 billion in value opportunity</a>.</li>
	<li>Japanese healthcare company&nbsp;<strong>Astellas Pharma Inc</strong>&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/alpmy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ALPMY</a>) has agreed to buy&nbsp;<strong>Iveric Bio Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/isee#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ISEE</a>) for $40.00 per share in cash for a total equity value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/05/32112605/astellas-pharma-acquires-iveric-bio-for-5-9b-to-focus-on-blindness-regeneration" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $5.9 billion</a>.</li>
	<li>Most recently,&nbsp;<strong>Bristol Myers Squibb &amp; Co</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bmy#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BMY</a>) has agreed to acquire&nbsp;<strong>RayzeBio Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ryzb#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">RYZB</a>) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/b36382478/bristol-myers-squibb-adds-premier-radiopharmaceutical-platform-with-acquisition-of-rayzebio" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">estimated cash acquired</a>.</li>
	<li><em>Image by Steve Buissinne from Pixabay</em></li>
</ul>
 

Comments

iShares Health Innovation Active ETF

News

Latest news for iShares Health Innovation Active ETF (ARCA:BMED)

Wednesday, January 22, 2025

Friday, December 29, 2023

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga